John Otrompke, BA, JD

News
Pembrolizumab Plus Chemotherapy Associated With EFS Advantage for Early-Stage TNBC
03/30/2022
The addition of pembrolizumab to chemotherapy for patients with early-stage triple-negative breast cancer was associated with a statistically significant advantage in estimated EFS at 36 months, according to results from the KEYNOTE-522 study.
The addition of pembrolizumab to chemotherapy for patients with early-stage triple-negative breast cancer was associated with a statistically significant advantage in estimated EFS at 36 months, according to results from the KEYNOTE-522 study.
The addition of pembrolizumab to...
03/30/2022
Oncology
News
Severe Actinic Keratoses Associated With Increased Risk of Squamous Cell Carcinoma
05/11/2022
Study findings identify severe actinic keratoses as a marker for increased incidence of cutaneous squamous cell carcinoma; this risk was substantially increased in patients who received additional treatment.
Study findings identify severe actinic keratoses as a marker for increased incidence of cutaneous squamous cell carcinoma; this risk was substantially increased in patients who received additional treatment.
Study findings identify severe...
05/11/2022
Oncology
News
Isatuximab Plus Pomalidomide and Dexamethasone: New Standard of Care for Relapsed/Refractory MM
03/02/2022
A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.
A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.
A novel combination of...
03/02/2022
Oncology
child scratching eczema
Conference Coverage
Fluctuating Course of Sleep Disorder Common in Adult Atopic Dermatitis Patients
03/28/2022
Almost half of adult patients with atopic dermatitis experienced a fluctuating course of sleep disorder, according to a dermatology practice-based study.
Almost half of adult patients with atopic dermatitis experienced a fluctuating course of sleep disorder, according to a dermatology practice-based study.
Almost half of adult patients...
03/28/2022
The Dermatologist
News
Adjuvant Chemotherapy Associated With Improved Survival in Locally Advanced Gastric Cancer
05/02/2022
Findings from a retrospective analysis suggest adjuvant chemotherapy improves overall survival in patients with locally advanced gastric cancer with a lymph node ratio of ≥9%.
Findings from a retrospective analysis suggest adjuvant chemotherapy improves overall survival in patients with locally advanced gastric cancer with a lymph node ratio of ≥9%.
Findings from a retrospective...
05/02/2022
Oncology
News
Four Doses of Rituximab Plus Induction Therapy Does Not Improve EFS in Patients With ALL
05/31/2022
Four doses of rituximab plus standard induction therapy did not significantly improve EFS over standard of care induction alone for patients with de-novo ALL.
Four doses of rituximab plus standard induction therapy did not significantly improve EFS over standard of care induction alone for patients with de-novo ALL.
Four doses of rituximab plus...
05/31/2022
Oncology
News
No Statistically Significant Impact of CXCR4 Mutations on Efficacy of Ibrutinib in WM
03/21/2022
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care...
03/21/2022
Oncology
News
Triplet Combination Based on Fractionated Docetaxel Does Not Improve Outcomes Over Standard Regimen in Advanced Gastric Cancer
05/05/2022
Fractionated docetaxel, oxaliplatin, and capecitabine did not demonstrate improved outcomes vs standard treatment with epirubicin, oxaliplatin, and capecitabine in inoperable, locally advanced or metastatic gastric cancer, according to the...
Fractionated docetaxel, oxaliplatin, and capecitabine did not demonstrate improved outcomes vs standard treatment with epirubicin, oxaliplatin, and capecitabine in inoperable, locally advanced or metastatic gastric cancer, according to the...
Fractionated docetaxel,...
05/05/2022
Oncology
rosacea flares
Conference Coverage
Patients With Diabetes Mellitus and Rosacea Have a Higher Five-Year Risk for Ocular Disease
03/26/2022
The researchers examined data from 4096 patients with diabetes and rosacea who received hypoglycemic agents between January 1, 1997 and December, 31, 2013.
The researchers examined data from 4096 patients with diabetes and rosacea who received hypoglycemic agents between January 1, 1997 and December, 31, 2013.
The researchers examined data...
03/26/2022
The Dermatologist
News
Early-Stage NSCLC Yearns Treatment Satisfaction Improvement
03/30/2022
Almost half (47%) of the subjects with early-stage non-small cell lung cancer (NSCLC) in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study did not undergo lymph node dissection...
Almost half (47%) of the subjects with early-stage non-small cell lung cancer (NSCLC) in the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) screening study did not undergo lymph node dissection...
Almost half (47%) of the...
03/30/2022
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use